|
Consensus recommendations |
Grade |
|
HCV qualitative PCR should be performed 12 weeks after cessation of DAA therapy. Opportunistic HCV qualitative PCR can be performed at any time beyond 4 weeks after cessation of DAA therapy, especially when there is concern about subsequent loss to follow-up, to confirm cure of hepatitis C (SVR4).
|
A1
A1
|
|
People with cirrhosis should continue in long-term surveillance programs:
* Exception: patients who achieve SVR, have normal liver function test results, have no cofactors for liver disease and show consistent post-treatment improvements, with LSM values of < 12 kPa and platelet counts ≥ 150 × 109/L, can be discharged from surveillance for CSPH (LSM and platelet counts or endoscopy), as they do not have CSPH and are at negligible risk of hepatic decompensation. These patients still require long-term surveillance for HCC. |
A1
|
|
People with no cirrhosis who achieve SVR and normal liver function test results should be medically managed as individuals who have never had HCV infection. |
B1 |
|
People with persistently abnormal liver function test results after SVR should undergo further assessment and monitoring for alternative causes of liver disease. |
A1 |
|
People with ongoing risk factors for the transmission of HCV infection should have at least annual HCV RNA testing performed. |
B1 |